CAROL EBERSOLE: Open Payments
NPI 1720479850 · FINDLAY, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$638 in 25 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $208 · 2025 $638
Food & beverage: $638
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 1 | $125 |
| Novartis Pharmaceuticals Corporation | 4 | $98 |
| CSL Behring | 4 | $76 |
| Optinose US, Inc. | 3 | $67 |
| Regeneron Healthcare Solutions, Inc. | 3 | $64 |
| Amgen Inc. | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| AstraZeneca Pharmaceuticals LP | 2 | $44 |
| Grifols USA, LLC | 2 | $39 |
| BioCryst US Sales Co., LLC | 1 | $21 |
Products named: NUCALA, Xhance, DUPIXENT, TEZSPIRE, Rhapsido, Hizentra, CUVITRU, Xembify.
Industry payments across OH — which companies pay providers there.
